Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure

被引:38
|
作者
Perianayagam, MC [1 ]
Murray, SL [1 ]
Balakrishnan, VS [1 ]
Guo, DQ [1 ]
King, AJ [1 ]
Pereira, BJG [1 ]
Jaber, BL [1 ]
机构
[1] Tufts Univ New England Med Ctr, Div Nephrol, Tupper Res Inst, Dept Med, Boston, MA 02111 USA
来源
关键词
D O I
10.1067/mlc.2000.109318
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Apoptosis, or programmed cell death, is an active form of cell death that is initiated by a number of stimuli and is intricately regulated, Apoptosis in both excessive and reduced amounts has pathophysiologic implications. Accelerated programmed cell death has been observed in leukocytes among patients with chronic renal failure (CRF). This has been ascribed in part to the retention of uremic toxins. The Fas/Fas ligand (FasL) system is a key regulatory apoptotic pathway, Membrane-bound Fas is a cell-surface receptor that transduces apoptosis after interaction with membrane-bound or soluble FasL (sFasL). By contrast, soluble Fas (sFas) binds sFasL and inhibits its activity. In an attempt to examine the balance between these soluble factors in uremia, we measured soluble sFas and sFasL levels in the serum of healthy control subjects and patients with various degrees of CRF and examined the distribution of the various molecular mass fractions of these proteins in uremic serum. In brief, serum was obtained from 15 healthy volunteers, 17 patients with CRF, 11 patients undergoing maintenance hemodialysis (HD), and 7 patients undergoing peritoneal dialysis (PD). Serum sFas and sFasL were measured by enzyme-linked immunosorbent assay, and their molecular distribution was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblot. Compared with results in healthy control subjects, sFas levels were significantly higher in patients with CRF and in patients undergoing dialysis. There was a significant inverse correlation between sFas levels and creatinine clearance. Serum sFasL levels were not different among the four groups. However, the sFas-to-sFasL ratio was significantly lower in healthy control subjects as compared with patients with CRF and patients undergoing dialysis. Immunoblots and densitometric analyses of sFas and sFasL depicted a known 48-kd sFas, a known 27-kd sFasL, and a 60-kd sFas-sFasL protein aggregate signal. In conclusion, serum sFas levels are increased in patients with various degrees of CRF and may bind circulating sFasL, thereby minimizing mediation of cellular apoptosis.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 50 条
  • [41] Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack
    O'Connell, J
    Bennett, MW
    O'Sullivan, GC
    Collins, JK
    Shanahan, F
    DISEASES OF THE ESOPHAGUS, 1999, 12 (02): : 83 - 89
  • [42] Plasma soluble Fas and soluble Fas ligand in chronic glomerulonephritis
    Sano, H
    Asano, K
    Minatoguchi, S
    Hiraoka, J
    Fujisawa, K
    Nishigaki, K
    Yasuda, N
    Kumada, H
    Takemura, M
    Ohashi, H
    Seishima, M
    Fujiwara, T
    Fujiwara, H
    NEPHRON, 1998, 80 (02) : 153 - 161
  • [43] Regulation of CD95/Fas signaling at the DISC
    I N Lavrik
    P H Krammer
    Cell Death & Differentiation, 2012, 19 : 36 - 41
  • [44] Clinical significance of serum soluble Fas, Fas ligand and Fas in intrahepatic lymphocytes in chronic hepatitis C
    El Sayed Zaki, Maysaa
    Auf, Fatma Abbas
    El Ghawalby, Nabieh Anwar
    El Saddal, Nirmeen Mohamed
    IMMUNOLOGICAL INVESTIGATIONS, 2008, 37 (02) : 163 - 170
  • [45] Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+ T lymphocytes
    Puppo, F
    Contini, P
    Ghio, M
    Brenci, S
    Scudeletti, M
    Filaci, G
    Ferrone, S
    Indiveri, F
    INTERNATIONAL IMMUNOLOGY, 2000, 12 (02) : 195 - 203
  • [46] Fas (CD95), Fas ligand (CD95L), and Bcl-2 expression in human placenta and umbilical cord.
    Uckan, D
    Steele, A
    Wang, B
    Chamizo, W
    Koutsonikolis, A
    Good, RA
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (01) : 114 - 114
  • [47] Membrane and soluble forms of Fas (CD95) in peripheral blood lymphocytes and in serum from burns patients
    Lebede, MJ
    Ptitsina, JS
    Vilkov, SA
    Korablev, SB
    Novikov, VV
    BURNS, 2001, 27 (07) : 669 - 673
  • [48] Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma
    Jodo, S
    Kobayashi, S
    Nakajima, Y
    Matsunaga, T
    Nakayama, N
    Ogura, N
    Kayagaki, N
    Okumura, K
    Koike, T
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1998, 112 (02): : 166 - 171
  • [49] Regulation of CD95/Fas signaling at the DISC
    Lavrik, I. N.
    Krammer, P. H.
    CELL DEATH AND DIFFERENTIATION, 2012, 19 (01): : 36 - 41
  • [50] Reference intervals of serum soluble APO-1 (Fas/CD95) concentrations in healthy adults
    Choi, JW
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2006, 36 (01): : 103 - 104